<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-03584381</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-04-27T13:23:23+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition</title>
            <author role="aut">
              <persName>
                <forename type="first">Delphine</forename>
                <surname>Morales</surname>
              </persName>
              <idno type="halauthorid">1643989-0</idno>
              <affiliation ref="#struct-537403"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Pascale</forename>
                <surname>Vigneron</surname>
              </persName>
              <idno type="halauthorid">240410-0</idno>
              <affiliation ref="#struct-537403"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Ines</forename>
                <surname>Ferreira</surname>
              </persName>
              <idno type="halauthorid">2435339-0</idno>
              <affiliation ref="#struct-537403"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Warda</forename>
                <surname>Hamitou</surname>
              </persName>
              <idno type="halauthorid">1643991-0</idno>
              <affiliation ref="#struct-537403"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Mikael</forename>
                <surname>Magnano</surname>
              </persName>
              <idno type="halauthorid">2435340-0</idno>
              <affiliation ref="#struct-537403"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Laxsika</forename>
                <surname>Mahenthiran</surname>
              </persName>
              <idno type="halauthorid">2435341-0</idno>
              <affiliation ref="#struct-537403"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Catherine</forename>
                <surname>Lok</surname>
              </persName>
              <email type="md5">db967c2efa982fd212e432bb266a5f04</email>
              <email type="domain">chu-amiens.fr</email>
              <idno type="idhal" notation="numeric">1509345</idno>
              <idno type="halauthorid" notation="string">656389-1509345</idno>
              <idno type="IDREF">https://www.idref.fr/071348832</idno>
              <affiliation ref="#struct-300535"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Muriel</forename>
                <surname>Vayssade</surname>
              </persName>
              <email type="md5">5a67ffd10bae4f04e21661ec0294d9c7</email>
              <email type="domain">utc.fr</email>
              <idno type="idhal" notation="string">muriel-vayssade</idno>
              <idno type="idhal" notation="numeric">1328762</idno>
              <idno type="halauthorid" notation="string">1476631-1328762</idno>
              <idno type="ORCID">https://orcid.org/0000-0003-2926-1776</idno>
              <affiliation ref="#struct-537403"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Muriel</forename>
                <surname>Vayssade</surname>
              </persName>
              <email type="md5">5a67ffd10bae4f04e21661ec0294d9c7</email>
              <email type="domain">utc.fr</email>
            </editor>
            <funder>This research was funded by the Hauts-de-France Region, the European Regional Development Fund (ERDF) 2014/2020, and Oise committee of “La Ligue contre le cancer”.</funder>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2023-12-21 11:37:16</date>
              <date type="whenModified">2026-04-27 12:26:02</date>
              <date type="whenReleased">2023-12-26 15:40:15</date>
              <date type="whenProduced">2021-10</date>
              <date type="whenEndEmbargoed">2023-12-21</date>
              <ref type="file" target="https://utc.hal.science/hal-03584381v1/document">
                <date notBefore="2023-12-21"/>
              </ref>
              <ref type="file" subtype="publisherPaid" n="1" target="https://utc.hal.science/hal-03584381v1/file/cancers-13-04761-v2.pdf" id="file-4357911-3792738">
                <date notBefore="2023-12-21"/>
              </ref>
              <ref type="externalLink" target="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507536"/>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="597531">
                <persName>
                  <forename>Muriel</forename>
                  <surname>Vayssade</surname>
                </persName>
                <email type="md5">5a67ffd10bae4f04e21661ec0294d9c7</email>
                <email type="domain">utc.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-03584381</idno>
            <idno type="halUri">https://utc.hal.science/hal-03584381</idno>
            <idno type="halBibtex">morales:hal-03584381</idno>
            <idno type="halRefHtml">&lt;i&gt;Cancers&lt;/i&gt;, 2021, 13 (19), pp.4761. &lt;a target="_blank" href="https://dx.doi.org/10.3390/cancers13194761"&gt;&amp;#x27E8;10.3390/cancers13194761&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Cancers, 2021, 13 (19), pp.4761. &amp;#x27E8;10.3390/cancers13194761&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 - Attribution<ref corresp="#file-4357911-3792738"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="UNIV-COMPIEGNE">Université de Technologie de Compiègne</idno>
            <idno type="stamp" n="BMBI" corresp="UNIV-COMPIEGNE">Laboratoire BMBI - Biomécanique et Bioingénierie</idno>
            <idno type="stamp" n="ALLIANCE-SU"> Alliance Sorbonne Université</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Delphine</forename>
                    <surname>Morales</surname>
                  </persName>
                  <idno type="halauthorid">1643989-0</idno>
                  <affiliation ref="#struct-537403"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Pascale</forename>
                    <surname>Vigneron</surname>
                  </persName>
                  <idno type="halauthorid">240410-0</idno>
                  <affiliation ref="#struct-537403"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Ines</forename>
                    <surname>Ferreira</surname>
                  </persName>
                  <idno type="halauthorid">2435339-0</idno>
                  <affiliation ref="#struct-537403"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Warda</forename>
                    <surname>Hamitou</surname>
                  </persName>
                  <idno type="halauthorid">1643991-0</idno>
                  <affiliation ref="#struct-537403"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Mikael</forename>
                    <surname>Magnano</surname>
                  </persName>
                  <idno type="halauthorid">2435340-0</idno>
                  <affiliation ref="#struct-537403"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Laxsika</forename>
                    <surname>Mahenthiran</surname>
                  </persName>
                  <idno type="halauthorid">2435341-0</idno>
                  <affiliation ref="#struct-537403"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Catherine</forename>
                    <surname>Lok</surname>
                  </persName>
                  <email type="md5">db967c2efa982fd212e432bb266a5f04</email>
                  <email type="domain">chu-amiens.fr</email>
                  <idno type="idhal" notation="numeric">1509345</idno>
                  <idno type="halauthorid" notation="string">656389-1509345</idno>
                  <idno type="IDREF">https://www.idref.fr/071348832</idno>
                  <affiliation ref="#struct-300535"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Muriel</forename>
                    <surname>Vayssade</surname>
                  </persName>
                  <email type="md5">5a67ffd10bae4f04e21661ec0294d9c7</email>
                  <email type="domain">utc.fr</email>
                  <idno type="idhal" notation="string">muriel-vayssade</idno>
                  <idno type="idhal" notation="numeric">1328762</idno>
                  <idno type="halauthorid" notation="string">1476631-1328762</idno>
                  <idno type="ORCID">https://orcid.org/0000-0003-2926-1776</idno>
                  <affiliation ref="#struct-537403"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">112113</idno>
                <idno type="issn">2072-6694</idno>
                <idno type="eissn">2072-6694</idno>
                <title level="j">Cancers</title>
                <imprint>
                  <publisher>MDPI</publisher>
                  <biblScope unit="volume">13</biblScope>
                  <biblScope unit="issue">19</biblScope>
                  <biblScope unit="pp">4761</biblScope>
                  <date type="datePub">2021-10</date>
                </imprint>
              </monogr>
              <idno type="doi">10.3390/cancers13194761</idno>
              <idno type="pubmedcentral">PMC8507536</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en">targeted therapy</term>
                <term xml:lang="en">tissue engineering</term>
                <term xml:lang="en">3D human melanoma model</term>
                <term xml:lang="en">BRAFi + MEKi efficiency</term>
                <term xml:lang="en">cancer-associated fibroblasts</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv">Life Sciences [q-bio]</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>The sensitivity of melanoma cells to targeted therapy compounds depends on the tumor microenvironment. Three-dimensional (3D) in vitro coculture systems better reflect the native structural architecture of tissues and are ideal for investigating cellular interactions modulating cell sensitivity to drugs. Metastatic melanoma (MM) cells (SK-MEL-28 BRAF V600E mutant and SK-MEL-2 BRAF wt) were cultured as a monolayer (2D) or cocultured on 3D dermal equivalents (with fibroblasts) and treated with a BRAFi (vemurafenib) combined with a MEK inhibitor (MEKi, cobimetinib). The drug combination efficiently inhibited 2D and 3D MM cell proliferation and survival regardless of their BRAF status. Two-dimensional and three-dimensional cancer-associated fibroblasts (CAFs), isolated from a cutaneous MM biopsy, were also sensitive to the targeted therapy. Conditioned media obtained from healthy dermal fibroblasts or CAFs modulated the MM cell’s response differently to the treatment: while supernatants from healthy fibroblasts potentialized the efficiency of drugs on MM, those from CAFs tended to increase cell survival. Our data indicate that the secretory profiles of fibroblasts influence MM sensitivity to the combined vemurafenib and cobimetinib treatment and highlight the need for 3D in vitro cocultures representing the complex crosstalk between melanoma and CAFs during preclinical studies of drugs.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-537403" status="VALID">
          <idno type="IdRef">282527842</idno>
          <idno type="RNSR">201220264D</idno>
          <idno type="ROR">https://ror.org/03yaydt41</idno>
          <orgName>Biomécanique et Bioingénierie</orgName>
          <orgName type="acronym">BMBI</orgName>
          <desc>
            <address>
              <addrLine>Université de Technologie de Compiègne - Centre de Recherche de Royallieu - rue du Docteur Schweitzer- CS 60319 - 60203 COMPIEGNE Cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://bmbi.utc.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-93027" type="direct"/>
            <relation name="UMR7338 / UMR6600" active="#struct-441569" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-300535" status="VALID">
          <orgName>CHU Amiens-Picardie</orgName>
          <desc>
            <address>
              <country key="FR"/>
            </address>
          </desc>
        </org>
        <org type="institution" xml:id="struct-93027" status="VALID">
          <idno type="ROR">https://ror.org/04y5kwa70</idno>
          <orgName>Université de Technologie de Compiègne</orgName>
          <orgName type="acronym">UTC</orgName>
          <desc>
            <address>
              <addrLine>Université de Technologie de Compiègne - rue du Docteur Schweitzer- CS 60319 - 60203 Compiègne Cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.utc.fr/</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>